



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A c c a c a e d e P e e ' R e b c f C a e d a b)
(Stock code: 9989)

**DL \ E I A I F C A E C ICA I **

Pursuant to new Rule 2.07A¹ of the Rules (the “ **\ , **”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ **\ E / , **”) and the articles of association of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “ **C \ , **”), the Company will disseminate the future corporate communications of the Company (the “ **C \ C \ , \ / **”²) to its Shareholders³ electronically and only send corporate communications in printed form to the Shareholders upon request.

In this connection, the following arrangements will come into effect on 31 December 2023.

**A A G E E **

- 1. **A \ . C \ C \ , \ / **⁴

The Company will send the Actionable Corporate Communications to Shareholders individually in electronic form by email. If the Company does not possess the email address of a Shareholder or the email address provided is not functional⁵, the Company will send the Actionable Corporate Communication in printed form together with a request form for soliciting the Shareholder’s functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

- 2. **C \ C \ , \ / **

The Company will make the Corporate Communications available on its website (www.hepalink.com) and the Stock Exchange’s website (www.hkexnews.hk).

The Company will not send a notice of publication of the Website Version⁶ of Corporate Communications to its Shareholders. The Shareholders are encouraged to proactively monitor the availability of all future Corporate Communications on the websites and access the Website Version⁶ of Corporate Communications by themselves.

✦ LI F. HA EH DE ' E AI ADD E. HE C ✦ A / ✦

In support of electronic communication by email, the Company recommends its Shareholders to provide the Company with their email address at any time in future by reasonable notice in writing to the Company's branch share registrar in Hong Kong at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to 9989-ecom@hk.tricorglobal.com.

To: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “Company”)
 c/o Tricor Investor Services Limited
 17/F, Far East Finance Centre
 16 Harcourt Road, Hong Kong

Information of Shareholders:

Name(s) (in English)	:	
Name(s) (in Chinese)	:	
Email address	:	
Email address (re-type)	:	
Contact telephone number	:	

Please mark (X) in ONLY ONE of the following boxes (English and Chinese):

<input type="checkbox"/>	To receive the English version ONLY for all future Corporate Communications and Actionable Corporate Communications;
<input type="checkbox"/>	To receive the Chinese version ONLY for all future Corporate Communications and Actionable Corporate Communications;
<input type="checkbox"/>	To receive the English and Chinese versions of all future Corporate Communications and Actionable Corporate Communications;
<input type="checkbox"/>	To receive prior request(s), if any, of printed version(s) of all future Corporate Communications and Actionable Corporate Communications. Shareholders will refer to the online versions to be published on the Company’s website and the website of The Stock Exchange of Hong Kong Limited for all future Corporate Communications or the electronic form of Actionable Corporate Communications to be received by email ⁴ (as the case may be).

Signature: _____

Address: _____

Contact telephone number: _____ Date: _____

- Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.
- Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders of the Company on how they wish to exercise their rights or make elections as the Company’s shareholders.
- If both English and Chinese versions of the Corporate Communications and Actionable Corporate Communications are combined into one document, a printed version of the Corporate Communications and Actionable Corporate Communications with both English and Chinese versions will be sent to the Shareholder requesting for a printed copy of any version(s) of the Corporate Communications and Actionable Corporate Communications.
- It is the Shareholder’s responsibility to provide email address that is functional. If the Company does not receive the completed form or the email address provided is not functional, the Company will send the Actionable Corporate Communication in printed form together with a request for soliciting your functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future. The Company will be considered to have complied with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any “non-delivery message”.
- Please complete all your details clearly. If no box, or more than one box, is marked, the Company reserves the right to treat this request as void.
- In the case of joint registered holders of any shares, this form shall be deemed to be submitted by the joint registered holder whose name first